BENEFIT Trial design: Patients with positive serologic tests for T. Cruzi and cardiomyopathy were randomized to benznidazole 300 mg daily for 40-80 days (n = 1,431) vs. placebo (n = 1,423). Results (p = 0.31) Death, cardiac arrest, ventricular tachycardia, pacemaker or ICD implantation, cardiac transplantation, heart failure, stroke, or other thromboembolic event: 27.5% of the benznidazole group vs. 29.1% of the placebo group (p = 0.31) Death: 17.2% vs. 18.1%, respectively for benznidazole vs. placebo 29.1 % 27.5 Conclusions Among patients with serologic evidence of T. Cruzi and chronic cardiomyopathy, benznidazole did not prevent adverse cardiac events compared with placebo at 7 years This lack of benefit was despite a higher rate of T. Cruzi conversion to negative status among the benznidazole group Benznidazoletherapy Placebo Morillo CA, et al. N Engl J Med 2015;373:1295-306